1. 国家自然科学基金面上项目（82373710），新型构象稳定的大环类FLT3抑制剂的设计、合成与抑制门控卡口氨基酸F691L突变导致的急性髓性白血病耐药活性研究，2024/01-2027/12，主持，49万

2. 国家自然科学基金面上项目（81973171），基于结构的新型选择性FLT3共价抑制剂的设计、合成及其对（复发性及预后不良）急性髓性白血病的生物活性研究，2020/01-2023/12，主持，55万

1. 国家自然科学基金面上项目（82373710），新型构象稳定的大环类FLT3抑制剂的设计、合成与抑制门控卡口氨基酸F691L突变导致的急性髓性白血病耐药活性研究，2024/01-2027/12，主持，49万

2. 国家自然科学基金面上项目（81973171），基于结构的新型选择性FLT3共价抑制剂的设计、合成及其对（复发性及预后不良）急性髓性白血病的生物活性研究，2020/01-2023/12，主持，55万

1. Nian-Guang Li* et al. PNPO-mediated Oxidation of DVL3 Promotes Multiple Myeloma Malignancy and Osteoclastogenesis by Activating the Wnt/β-catenin Pathway. Advanced Science, 2025, 12(5), 2407681.(IF14.2994)

2. Nian-Guang Li* et al. Design, Synthesis and Biological Evaluation of 3,4-Dihydroisoquinolin-1(2H)-one Derivatives as Protein Arginine Methyltransferase 5 Inhibitors for the Treatment of non-Hodgkin’s Lymphoma. Journal of Medicinal Chemistry, 2025, 68(1), 108-134.(IF6.7996)

3. Nian-Guang Li* et al.Discovery of SILA-123 as a Highly Potent FLT3 Inhibitor for the Treatment of Acute Myeloid Leukemia with Various FLT3 Mutations. Journal of Medicinal Chemistry, 2024, 67(24), 21752-21780.(IF6.7996)

4. Nian-Guang Li* et al. The Discovery of 1-(Phenylsulfonyl)-1,2,3,4-tetrahydroquinoline Derivative as Orally Bioavailable and Safe RORγt Inverse Agonist for the Treatment of Rheumatoid Arthritis. Journal of Medicinal Chemistry, 2024, 67(22), 20315-20342.(IF6.7996)

5. Nian-Guang Li* et al. Discovery of RORγ Allosteric Fluorescent Probes and the Application: Fluorescence Polarization, Screening and Bioimaging. Journal of Medicinal Chemistry, 2024, 67(5), 4194−4224. (IF6.7996)

6. Nian-Guang Li* et al.Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.Journal of Medicinal Chemistry, 2024, 67(6), 6, 4346-4375. (IF6.7996)

7. Nian-Guang Li* et al. Medicinal chemistry strategies for the development of Bruton’s tyrosine kinase inhibitors against resistance. Journal of Medicinal Chemistry, 2022, 65, 7415−7437. (IF6.7996)

8. Nian-Guang Li* et al. Small-molecule Fms-like tyrosine kinase 3 inhibitors: An attractive and efficient method for the treatment of acute myeloid leukemia. Journal of Medicinal Chemistry, 2020, 63(21), 12403−12428. (IF6.7996)

9. Nian-Guang Li* et al. AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma. Journal of Experimental & Clinical Cancer Research, 2022, 41:11. (IF 11.3997)

10. Nian-Guang Li* et al. Kinase-Bench: Comprehensive Benchmarking Tools and Guidance for Achieving Selectivity in Kinase Drug Discovery. Journal of Chemical Information and Modeling, 2024, 64(24), 9528−9550.(IF5.5999)